Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2017

Open Access 01.12.2017 | Research article

Very early recurrence predicts long-term outcome in patients after atrial fibrillation catheter ablation: a prospective study

verfasst von: Yangjing Xue, Xiaoning Wang, Saroj Thapa, Luping Wang, Jiaoni Wang, Zhiqiang Xu, Shaoze Wu, Luyuan Tao, Guoqiang Wang, Lu Qian, Lianming Liao, Baohua Liu, Kangting Ji

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2017

Abstract

Background

Long-term recurrence (LR) is a tendency that re-occurs within 3 months after catheter ablation for atrial fibrillation (AF). Whether very early recurrence (VER) within 7 days of post ablation is a prognostic factor of LR or not is unclear. For this reason, present study sought to examine the relationship between VER and LR.

Methods

In this prospective analysis 378 consecutive patients underwent an initial catheter ablation for paroxysmal or persistent AF. The association between VER and LR was analyzed by univariate and multivariate Cox regression, as well as time-dependent receiver operator characteristic (ROC) analysis.

Results

After a mean follow-up of 14.71 ± 8.58 months, 81 (65.90%) patients with VER experienced LR and were associated with lower event of free survival from LR (Log rank test, P < 0.001). Multivariate Cox regression analysis revealed that VER (HR = 7.02, 95% CI = 4.78–10.31; P < 0.001), left atrial enlargement (HR = 2.92, 95% CI = 1.88–4.54; P < 0.001), tendency in advanced age (HR = 1.50, 95% CI = 0.99–2.28; P = 0.054), and tendency in male (HR = 0.71, 95% CI = 0.50–1.01; P = 0.060) were independent predictors of LR. According to time-dependent ROC analysis, it was found that VER was more sensitive than common risk factors in predicting LR (0.74 vs 0.66, P < 0.001) and combination model further improved the C statistic for predicting LR (0.82 vs 0.66, P < 0.001).

Conclusions

After a single procedure of catheter ablation, patients with VER were strongly associated with LR and combination of VER and common risk factors could further improve prediction of patients who were at high risk for LR.
Abkürzungen
AADs
Anti-arrhythmic drugs
AF
Atrial fibrillation
AT
Atrial tachyarrhythmia
LA
Left atria
LR
Long-term recurrence
PVI
Pulmonary vein isolation
PVs
Pulmonary veins
ROC
Receiver operator characteristic
VER
Very early recurrence

Background

Catheter ablation is the mainstay therapy for atrial fibrillation (AF), but the high rate of long-term recurrence (LR) is a limitation of the procedure. Non-paroxysmal AF, sleep apnea, obesity, left atrial enlargement, advanced age, hypertension, left atrial fibrosis and recurrence of AF within the first 3 months after catheter ablation have been identified to be the LR predictors [114]. Among them, recurrence of AF within the first 3 months is considered to be the most important predictor of long-term treatment failure [514]. Based on these studies, a so-called blanking period, the duration ranging from the first 7 days to 3 months post ablation, is proposed [515].
In the clinical practice, it has been found that lots of patients had episodes of AF as early as 7 days of post ablation. In the present study, it was aimed to examine the relationship of recurrence within 7 days, which we defined as very early recurrence (VER), and LR after 3 months. We hypothesized that VER was a prognostic factor of LR after 3 months.

Methods

This prospective study included 378 consecutive patients with paroxysmal (n = 168) or persistent (n = 210) AF who underwent an initial ablation at the Second Affiliated hospital and Yuying Children’s Hospital of Wenzhou Medical University, from January 2013 and December 2014.
Paroxysmal AF is defined as AF that terminates spontaneously or under anti-arrhythmic drugs (AADs) within 7 days of onset. Persistent AF is defined as continuous AF sustaining for more than 7 days. Patients were excluded if they aged <20, had pregnancy, prior cardiac surgery, implanted pacemaker, chronic renal failure requiring hemodialysis, and severe mitral valve disease. All patients gave written informed consent and the study protocol was approved by our institutional review board.
For every patient, step-wise ablation strategy was performed, including circumferential pulmonary vein isolation (PVI), complex fractionated atrial electrograms, and linear ablation. The electrophysiological evaluation of PVI was bi-directional conduction block between left atria (LA) and pulmonary veins (PVs). Whether to perform additional ablation including tricuspid valve isthmus ablation, continuous fractionated atrial electrogram ablation, and LA linear ablation was decided by the operator and/or the attending physician. The ablation procedure followed the method described by Liu X et al. [16, 17].
After the ablation procedure, patients remained hospitalized under continuous electrocardiography monitoring for at least 7 days. Patients received 24 h Holter monitoring at 3, 6 and 12 months follow-ups after procedure and every 12 months thereafter. Among follow-ups, all patients were encouraged to visit doctors for ECGs or Holter monitoring for any symptoms suggestive of AT onset.
AADs continued for 1–3 months after the ablation procedure. LR was defined as any asymptomatic or symptomatic atrial tachyarrhythmia (AT) lasting >30s off AADs after the initial 3-month blanking period. VER was defined as sustained AT (lasting >30s) on or off AADs recurred within 7 days post ablation.

Statistical analysis

Depending on the distribution, the continuous data were presented as median (25th–75th percentiles) or as mean ± SD. Categorical data were presented as counts or proportions. The differences between groups were assessed with the χ2 test or Fisher’s exact test for categorical data and the nonparametric Wilcoxon rank-sum test or Student test for continuous data.
Factors associated with recurrence arrhythmia during follow-ups were assessed in univariate and multivariable Cox proportional hazard models. Factors with P values <0.1 in univariate analyses were included in stepwise multivariate Cox regression models. Time-dependent receiver operator characteristic (ROC) curve analysis was generated to test the predictive discrimination of patients with or without LR. A two-tailed value of P < 0.05 was considered to indicate the statistical significance.

Results

Baseline characteristics of patients are summarized in Table 1. AF was paroxysmal in 168 (44.44%) patients and persistent in 210 (55.56%). Only 6 patients had moderate valvular heart disease. Risk of thromboembolic (CHADS2 and CHADS-VASc Score) and bleeding (HAS-BLED Score) complications were both significantly high in patients with LR. Warfarin usage at hospital discharge tended to be more frequent in patients with LR (P = 0.089). Advanced age (age ≥ 65 years), female gender, increased BMI, persistent AF, hypertension, diabetes, history of heart failure (HF), decreased left ventricular ejection fraction (EF), left atrial enlargement (left atrial ≥50 mm), statins usage, and ACEI/ARB usage were significantly more frequent in patients with LR.
Table 1
Baseline characteristics of the Patientsa
Variables
Total
Long-term recurrence
P-value
N = 378
Without N = 255
With N = 123
Age, years
65.37 ± 10.44
63.69 ± 10.40
68.85 ± 9.68
<0.001
 Age ≥ 65 years, n (%)
222 (58.70%)
131 (51.40%)
91 (74.00%)
<0.001
Male, n (%)
215 (56.90%)
156 (61.20%)
59 (48.00%)
0.015
BMI, kg/m2
24.43 ± 3.08
24.07 ± 3.00
25.17 ± 3.15
0.001
Type of AF
 Paroxysmal, n (%)
168 (44.40%)
128 (50.20%)
40 (32.50%)
0.001
 Persistent, n (%)
210 (55.60%)
127 (49.80%)
87 (67.50%)
0.001
Duration of AF, months
32.11 ± 44.82
33.44 ± 48.54
29.37 ± 35.91
0.409
Hypertension, n (%)
223 (59.00%)
141 (55.30%)
82 (66.70%)
0.035
 Systolic BP, mmHg
135.17 ± 20.83
134.39 ± 21.27
136.80 ± 19.88
0.291
 Diastolic BP, mmHg
82.94 ± 51.28
81.76 ± 42.34
85.39 ± 66.21
0.520
Diabetes, n (%)
56 (14.80%)
30 (11.80%)
26 (21.10%)
0.016
 FBG, mmol/L
5.14 ± 1.15
5.09 ± 1.02
5.26 ± 1.39
0.117
History of HF, n (%)
46 (12.20%)
20 (7.80%)
26 (21.10%)
<0.001
Left ventricular EF, %
63.48 ± 7.52
63.82 ± 7.35
62.78 ± 7.85
0.211
Left atrial dimension, mm
40.82 ± 6.41
39.50 ± 5.72
43.56 ± 6.91
<0.001
Left atrial 50 mm, n (%)
39 (10.30%)
13 (5.10%)
26 (21.10%)
<0.001
Moderate valvular heart disease, n (%)
6 (1.60%)
3 (1.20%)
3 (2.40%)
0.357
CAD, n (%)
26 (6.90%)
12 (4.70%)
14 (11.40%)
0.016
Prior Stroke/TIA, n (%)
49 (13.00%)
31 (12.20%)
18 (14.60%)
0.502
CHADS2 Score
1.34 ± 1.19
1.17 ± 1.10
1.71 ± 1.30
<0.001
CHA2DS2-VASc Score
2.81 ± 1.81
2.49 ± 1.70
3.48 ± 1.83
<0.001
HAS-BLED Score
2.47 ± 1.06
2.32 ± 1.02
2.79 ± 1.07
<0.001
CRP within 24 h post-procedure, mg/dL
6.36 ± 10.27
6.38 ± 10.87
6.32 ± 8.94
0.954
Medication at hospital discharge
Oral anticoagulant
 Warfarin, n (%)
297 (78.57%)
194 (76.10%)
103 (83.70%)
0.089
 Dabigatran, n (%)
73 (19.31%)
54 (21.20%)
19 (15.40%)
0.186
 Xa inhibitor, n (%)
8 (2.12%)
7 (2.70%)
1 (0.80%)
0.221
Statins, n (%)
269 (71.20%)
174 (68.20%)
95 (77.20%)
0.070
ACEI/ARB, n (%)
169 (44.70%)
103 (40.40%)
66 (53.70%)
0.015
Beta-blockers, n (%)
111 (29.40%)
70 (27.50%)
41 (33.30%)
0.239
Vaughan Williams class I or III AAD, n (%)
342 (90.50%)
235 (92.20%)
107 (87.00%)
0.109
Amiodarone, n (%)
328 (86.80%)
228 (89.40%)
100 (81.30%)
0.029
Propafenon, n (%)
14 (3.70%)
7 (2.70%)
7 (5.70%)
0.155
BMI body mass index, AF atrial fibrillation, FBG fasting blood glucose, HF heart failure, EF ejection fraction, CAD coronary artery disease, TIA transient ischemic attack, CRP C-reactive protein, AAD anti-arrhythmia drug
aPlus-minus values are means ± SD. Percentages do not sum to 100 because of rounding
After a single ablation procedure, 112 patients (29.63%) experienced VER within the first 7 days post ablation while LR cumulatively occurred in 123 (32.54%) patients after the initial 3-month blanking period. Among these 112 patients with VER, 81 (65.90%) patients experienced LR (Fig. 1).
Figure 2 shows the event-free survival from the LR for patients with and without VER within 7 days. After a mean follow-up of 14.71 ± 8.58 months, patients with VER were associated with LR (Log rank test, P < 0.001).
Univariate Cox analysis was performed and identified that VER was associated with LR (P < 0.10), and similarly to the factors including advanced age (age ≥ 65 years), BMI, persistent AF, duration of AF, hypertension, diabetes, history of heart failure, left ventricular EF, left atrial enlargement, ACEI/ARB usage. In multivariable Cox regression analysis, independent predictors of LR in this study were VER (HR = 7.02, 95% CI = 4.78–10.31; P < 0.001), left atrial enlargement (HR = 2.92, 95% CI = 1.88–4.54; P < 0.001), tendency in advanced age (age ≥ 65 years) (HR = 1.50, 95% CI = 0.99–2.28; P = 0.054), and tendency in male (HR = 0.71, 95% CI = 0.50–1.01; P = 0.060) (Table 2).
Table 2
The results of the multivariable Cox regression analysis of the independent correlates for the LR
Parameters
OR
95% CI Low
95% CI Upp
P-value
VER
7.02
4.78
10.31
<0.001
Left atrial enlargement
2.92
1.88
4.54
<0.001
Advanced age
1.50
0.99
2.28
0.054
Male
0.71
0.50
1.01
0.060
LR Long-term recurrence, VER Very Early Recurrence
To further assess the potential prognostic value of VER in predicting cumulative LR, we performed time-dependent ROC analysis. C statistic for VER was significantly greater than model based on established common risk factors (left atrial enlargement, age ≥ 65, male) in this study (0.74 vs 0.66, P < 0.001) (Fig. 3). When VER was combined with the established common risk factors, VER improved the C statistic (0.82 vs 0.66, P < 0.001), indicating that the combination of VER with common risk factors has a greater potential to predict LR (Fig. 4).

Discussion

The major findings of this study are as follows; after a single procedure of catheter ablation for paroxysmal or persistent AF, (1) Above half of patients with VER (65.90%) experienced subsequent LR and were associated with lower event-free survival from LR, (2) VER was an independent predictor of LR after adjustment for common risk factors of AF, (3) VER was more sensitive than common risk factors in predicting LR and combination model was superior in predicting LR.
The purpose of catheter ablation is to eliminate underlying cardiac arrhythmia by destroying myocardial tissue through energy. However, due to the complexity of the underlying pathological mechanisms, AF recurs frequently after an initially successful ablation procedure. Reported frequency of LR ranges from 5 to 63%, depending on method and intensity of surveillance, technique used, patient characteristics, and definition of success, with a mean overall successful rate of approximately 70% [18]. In the present study, we found the cumulative LR was about 32.54% at a mean follow-up of 14.71 ± 8.58 months after a single procedure. Among most patients, AF recurred within 7 days.
Recurrence within 3 months following catheter ablation is relatively common regardless of catheter techniques used and is a predictor of LR [514]. However, definitions of recurrence time point within the blanking period vary in the reported studies. Arya et al. [9] defined early recurrence as a sustained episode of AF within 7 days immediately after the procedure, while others defined it by a sustained episode of AF within 2 weeks, [5] 1 month, [6, 7] 6 weeks, [8, 10] and 3 months [1114] during the blanking period. The optimal time to define early recurrence remains to be determined. In this study, we defined sustained AT episode within 7 days as VER since 112 patients (29.63%) experienced it. By using multivariate Cox analysis, VER independently predicted subsequent LR. Mechanisms of arrhythmia recurrence within 3 months of post ablation remain to be fully elucidated and may include reconnection of the PVs, [19] inflammatory response to thermal injury and/or pericarditis, [20, 21] imbalance of the autonomic nervous system, [22, 23] and a delayed effect of AF ablation [23, 24].
The use of 3-month blanking period has been proposed on the assumption that early recurrence will lead to delayed cure and should not prompt immediate re-ablation attempts [15, 2527]. However, patients with early recurrence and delayed cure were of varied proportion [2527] and the mechanisms and significance of early arrhythmia remains unclear [1924]. Given the fact that early recurrence is a strong prognostic factor of LR, delayed re-intervention of tachyarrhythmia within blanking period may be a cause of failure to prevent LR. Indeed, Lellouche et al. [7] evaluated the use of early re-ablation on long-term outcome among patients with early recurrence. After a mean follow-up of 11 ± 11 months, patients with early re-ablation had a lower rate of clinical recurrences. Thus, detection of patients who are at high risk for LR and strategies of aggressive re-intervention may improve at long-term outcome. In our study, VER was more sensitive than common risk factors in prediction of LR. Moreover, when combining VER with common risk factors, it could further improve prediction of LR.
It must be noted that there are limitations in our study. Above all, it is a prospective cohort study and should be validated in large randomized controlled studies. Furthermore, monitoring of atrial tachyarrhythmia recurrence was based on the review of 12-lead electrocardiograms and Holter recordings at follow-up visits. It is likely that more invasive and detailed monitoring of atrial tachyarrhythmia should be offered. Finally, the precise mechanisms of VER and strategies to prevent VER were not investigated and required further research.

Conclusions

To sum up, the results of this study confirm that VER is observed frequently after a single procedure of catheter ablation and it was strongly associated with LR. Combination between VER and common risk factors could further improve prediction of patients who were at high risk for LR. Whether more aggressively invasive examinations and interventions are helpful for these patients, deserve further studies.

Acknowledgements

Not Applicable.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions

KTJ and BHL analyzed and interpreted the patient data. YJX and XNW both were major contributors in writing the manuscript. YJX, XNW, ST, LPW, JNW, ZQX, SZW, LYT, GQW, LQ participated in data acquisition. YJX and LML performed statistical analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
Not applicable.
The study was approved by the institutional review board of the Second Affiliated hospital and Yuying Children’s Hospital of Wenzhou Medical University, and all patients provided written informed consent.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Kokturk B, Konstantinidou M, Metzner A, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122(23):2368–77.CrossRefPubMed Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Kokturk B, Konstantinidou M, Metzner A, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122(23):2368–77.CrossRefPubMed
2.
Zurück zum Zitat Tzou WS, Marchlinski FE, Zado ES, Lin D, Dixit S, Callans DJ, Cooper JM, Bala R, Garcia F, Hutchinson MD, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):237–42.CrossRefPubMed Tzou WS, Marchlinski FE, Zado ES, Lin D, Dixit S, Callans DJ, Cooper JM, Bala R, Garcia F, Hutchinson MD, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):237–42.CrossRefPubMed
3.
Zurück zum Zitat Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57(2):160–6.CrossRefPubMed Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57(2):160–6.CrossRefPubMed
4.
Zurück zum Zitat Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, Komatsu Y, Roten L, Jadidi A, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol. 2015;8(1):18–24.CrossRefPubMed Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, Komatsu Y, Roten L, Jadidi A, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol. 2015;8(1):18–24.CrossRefPubMed
5.
Zurück zum Zitat Oral H, Knight BP, Ozaydin M, Tada H, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi Jr F, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40(1):100–4.CrossRefPubMed Oral H, Knight BP, Ozaydin M, Tada H, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi Jr F, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40(1):100–4.CrossRefPubMed
6.
Zurück zum Zitat Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL, Ueng KC, Cheng JJ, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2004;10(3):221–6.CrossRefPubMed Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL, Ueng KC, Cheng JJ, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2004;10(3):221–6.CrossRefPubMed
7.
Zurück zum Zitat Lellouche N, Jais P, Nault I, Wright M, Bevilacqua M, Knecht S, Matsuo S, Lim KT, Sacher F, Deplagne A, et al. Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation. J Cardiovasc Electrophysiol. 2008;19(6):599–605.CrossRefPubMed Lellouche N, Jais P, Nault I, Wright M, Bevilacqua M, Knecht S, Matsuo S, Lim KT, Sacher F, Deplagne A, et al. Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation. J Cardiovasc Electrophysiol. 2008;19(6):599–605.CrossRefPubMed
8.
Zurück zum Zitat Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Russo AM, et al. Antiarrhythmics after ablation of Atrial fibrillation (5A study). Circulation. 2009;120(12):1036–40.CrossRefPubMed Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Russo AM, et al. Antiarrhythmics after ablation of Atrial fibrillation (5A study). Circulation. 2009;120(12):1036–40.CrossRefPubMed
9.
Zurück zum Zitat Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, Bode K, Husser D, Kottkamp H, Piorkowski C. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace. 2010;12(2):173–80.CrossRefPubMed Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, Bode K, Husser D, Kottkamp H, Piorkowski C. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace. 2010;12(2):173–80.CrossRefPubMed
10.
Zurück zum Zitat Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, et al. Antiarrhythmics after ablation of atrial fibrillation (5A study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011;4(1):11–4.CrossRefPubMed Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, et al. Antiarrhythmics after ablation of atrial fibrillation (5A study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011;4(1):11–4.CrossRefPubMed
11.
Zurück zum Zitat Pokushalov E, Romanov A, Corbucci G, Bairamova S, Losik D, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. 2012;9(9):1375–9.CrossRefPubMed Pokushalov E, Romanov A, Corbucci G, Bairamova S, Losik D, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. 2012;9(9):1375–9.CrossRefPubMed
12.
Zurück zum Zitat Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, Morishima I, Miura F, Watanabe T, Masuda M, et al. Efficacy of Antiarrhythmic drugs short-term use after catheter ablation for Atrial fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7):610–8.CrossRefPubMed Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, Morishima I, Miura F, Watanabe T, Masuda M, et al. Efficacy of Antiarrhythmic drugs short-term use after catheter ablation for Atrial fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7):610–8.CrossRefPubMed
13.
Zurück zum Zitat Themistoclakis S, Schweikert RA, Saliba WI, Bonso A, Rossillo A, Bader G, Wazni O, Burkhardt DJ, Raviele A, Natale A. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm. 2008;5(5):679–85.CrossRefPubMed Themistoclakis S, Schweikert RA, Saliba WI, Bonso A, Rossillo A, Bader G, Wazni O, Burkhardt DJ, Raviele A, Natale A. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm. 2008;5(5):679–85.CrossRefPubMed
14.
Zurück zum Zitat Koyama T, Sekiguchi Y, Tada H, Arimoto T, Yamasaki H, Kuroki K, Machino T, Tajiri K, Zhu XD, Kanemoto M, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol. 2009;103(9):1249–54.CrossRefPubMed Koyama T, Sekiguchi Y, Tada H, Arimoto T, Yamasaki H, Kuroki K, Machino T, Tajiri K, Zhu XD, Kanemoto M, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol. 2009;103(9):1249–54.CrossRefPubMed
15.
Zurück zum Zitat Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano Jr RJ, Davies DW, Di Marco J, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of Atrial fibrillation. Developed in partnership with the European heart rhythm association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European cardiac arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European cardiac arrhythmia Society, the European heart rhythm association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632–696 e621.CrossRefPubMed Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano Jr RJ, Davies DW, Di Marco J, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of Atrial fibrillation. Developed in partnership with the European heart rhythm association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European cardiac arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European cardiac arrhythmia Society, the European heart rhythm association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632–696 e621.CrossRefPubMed
16.
Zurück zum Zitat Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F, Zhou L, Gu JN. Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and rheumatic heart disease: a randomized trial. Eur Heart J. 2010;31(21):2633–41.CrossRefPubMed Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F, Zhou L, Gu JN. Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and rheumatic heart disease: a randomized trial. Eur Heart J. 2010;31(21):2633–41.CrossRefPubMed
17.
Zurück zum Zitat Zhang XD, Gu J, Jiang WF, Zhao L, Zhou L, Wang YL, Liu YG, Liu X. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J. 2014;35(20):1327–34.CrossRefPubMed Zhang XD, Gu J, Jiang WF, Zhao L, Zhou L, Wang YL, Liu YG, Liu X. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J. 2014;35(20):1327–34.CrossRefPubMed
18.
Zurück zum Zitat Marine JE. Catheter ablation therapy for supraventricular arrhythmias. JAMA. 2007;298(23):2768–78.CrossRefPubMed Marine JE. Catheter ablation therapy for supraventricular arrhythmias. JAMA. 2007;298(23):2768–78.CrossRefPubMed
20.
Zurück zum Zitat Grubman E, Pavri BB, Lyle S, Reynolds C, Denofrio D, Kocovic DZ. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardiovasc Electrophysiol. 1999;10(3):336–42.CrossRefPubMed Grubman E, Pavri BB, Lyle S, Reynolds C, Denofrio D, Kocovic DZ. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardiovasc Electrophysiol. 1999;10(3):336–42.CrossRefPubMed
21.
Zurück zum Zitat Tanno K, Kobayashi Y, Kurano K, Kikushima S, Yazawa T, Baba T, Inoue S, Mukai H, Katagiri T. Histopathology of canine hearts subjected to catheter ablation using radiofrequency energy. Jpn Circ J. 1994;58(2):123–35.CrossRefPubMed Tanno K, Kobayashi Y, Kurano K, Kikushima S, Yazawa T, Baba T, Inoue S, Mukai H, Katagiri T. Histopathology of canine hearts subjected to catheter ablation using radiofrequency energy. Jpn Circ J. 1994;58(2):123–35.CrossRefPubMed
22.
Zurück zum Zitat Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004;109(3):327–34.CrossRefPubMed Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004;109(3):327–34.CrossRefPubMed
23.
Zurück zum Zitat Hsieh MH, Chiou CW, Wen ZC, Wu CH, Tai CT, Tsai CF, Ding YA, Chang MS, Chen SA. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation. 1999;100(22):2237–43.CrossRefPubMed Hsieh MH, Chiou CW, Wen ZC, Wu CH, Tai CT, Tsai CF, Ding YA, Chang MS, Chen SA. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation. 1999;100(22):2237–43.CrossRefPubMed
24.
Zurück zum Zitat Langberg JJ, Borganelli SM, Kalbfleisch SJ, Strickberger SA, Calkins H, Morady F. Delayed effects of radiofrequency energy on accessory atrioventricular connections. Pacing Clin Electrophysiol. 1993;16(5 Pt 1):1001–5.CrossRefPubMed Langberg JJ, Borganelli SM, Kalbfleisch SJ, Strickberger SA, Calkins H, Morady F. Delayed effects of radiofrequency energy on accessory atrioventricular connections. Pacing Clin Electrophysiol. 1993;16(5 Pt 1):1001–5.CrossRefPubMed
25.
Zurück zum Zitat O'Donnell D, Furniss SS, Dunuwille A, Bourke JP. Delayed cure despite early recurrence after pulmonary vein isolation for atrial fibrillation. Am J Cardiol. 2003;91(1):83–5.CrossRefPubMed O'Donnell D, Furniss SS, Dunuwille A, Bourke JP. Delayed cure despite early recurrence after pulmonary vein isolation for atrial fibrillation. Am J Cardiol. 2003;91(1):83–5.CrossRefPubMed
26.
Zurück zum Zitat Bertaglia E, Stabile G, Senatore G, Zoppo F, Turco P, Amellone C, De Simone A, Fazzari M, Pascotto P. Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation. Pacing Clin Electrophysiol. 2005;28(5):366–71.CrossRefPubMed Bertaglia E, Stabile G, Senatore G, Zoppo F, Turco P, Amellone C, De Simone A, Fazzari M, Pascotto P. Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation. Pacing Clin Electrophysiol. 2005;28(5):366–71.CrossRefPubMed
27.
Zurück zum Zitat Jiang H, Lu Z, Lei H, Zhao D, Yang B, Huang C. Predictors of early recurrence and delayed cure after segmental pulmonary vein isolation for paroxysmal atrial fibrillation without structural heart disease. J Interv Card Electrophysiol. 2006;15(3):157–63.CrossRefPubMed Jiang H, Lu Z, Lei H, Zhao D, Yang B, Huang C. Predictors of early recurrence and delayed cure after segmental pulmonary vein isolation for paroxysmal atrial fibrillation without structural heart disease. J Interv Card Electrophysiol. 2006;15(3):157–63.CrossRefPubMed
Metadaten
Titel
Very early recurrence predicts long-term outcome in patients after atrial fibrillation catheter ablation: a prospective study
verfasst von
Yangjing Xue
Xiaoning Wang
Saroj Thapa
Luping Wang
Jiaoni Wang
Zhiqiang Xu
Shaoze Wu
Luyuan Tao
Guoqiang Wang
Lu Qian
Lianming Liao
Baohua Liu
Kangting Ji
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2017
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0533-2

Weitere Artikel der Ausgabe 1/2017

BMC Cardiovascular Disorders 1/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.